Department of Neurology (Division of Neurocritical Care), Washington University in St. Louis School of Medicine, St. Louis, Missouri.
Neurosurgery. 2019 Aug 1;85(2):223-230. doi: 10.1093/neuros/nyy240.
Induced hypertension (IH) remains the mainstay of medical management for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH). However, raising blood pressure above normal levels may be associated with systemic and neurological complications, of which posterior reversible encephalopathy syndrome (PRES) has been increasingly recognized.
To ascertain the frequency and predisposing factors for PRES during IH therapy.
We identified 68 patients treated with IH from 345 SAH patients over a 3-yr period. PRES was diagnosed based on clinical suspicion, confirmed by imaging. We extracted additional data on IH, including baseline and highest target mean arterial pressure (MAP), comparing PRES to IH-treated controls.
Five patients were diagnosed with PRES at median 6.6 d (range 1-8 d) from vasopressor initiation. All presented with lethargy, 3 had new focal deficits, and 1 had a seizure. Although baseline MAP (prior to DCI) did not differ between cases and controls, both MAP immediately prior to IH (112 vs 90) and highest MAP targeted were greater (140 vs 120 mm Hg, both P < .01). Magnitude of MAP elevation was greater (54 vs 34 above baseline, P = .004) while degree of IH was not (37 vs 38 above pre-IH MAP). All 4 surviving PRES patients had complete resolution with IH discontinuation.
PRES was diagnosed in 7% of SAH patients undergoing IH therapy, most often when MAP was raised well above baseline to levels that exceed traditional autoregulatory thresholds. High suspicion for this reversible disorder appears warranted in the face of unexplained neurological deterioration during aggressive IH.
在蛛网膜下腔出血(SAH)后,诱导高血压(IH)仍然是治疗迟发性脑缺血(DCI)的主要方法。然而,将血压升高到正常水平以上可能与全身和神经系统并发症相关,其中后部可逆性脑病综合征(PRES)已越来越受到关注。
确定 IH 治疗期间 PRES 的频率和易患因素。
我们在 3 年期间从 345 例 SAH 患者中确定了 68 例接受 IH 治疗的患者。根据临床怀疑,通过影像学确诊 PRES。我们提取了 IH 的其他数据,包括基线和最高目标平均动脉压(MAP),并将 PRES 与 IH 治疗对照组进行比较。
在开始使用升压药后中位数 6.6 天(范围 1-8 天)时,有 5 例患者被诊断为 PRES。所有患者均表现为嗜睡,3 例出现新的局灶性缺损,1 例出现癫痫发作。尽管病例和对照组之间的基线 MAP(在 DCI 之前)没有差异,但 IH 之前的 MAP(112 与 90)和目标最高 MAP 都更高(140 与 120mmHg,均 P<0.01)。MAP 升高幅度更大(高于基线 54mmHg,P=0.004),而 IH 程度没有(高于 IH 前 MAP 37mmHg)。所有 4 例 PRES 存活患者在停止 IH 后完全缓解。
在接受 IH 治疗的 SAH 患者中,7%的患者被诊断为 PRES,最常见于 MAP 升高至远高于基线水平,超过传统自动调节阈值的情况。在积极进行 IH 治疗时,出现不明原因的神经功能恶化,应高度怀疑这种可逆性疾病。